Core Viewpoint - The company reported a decline in both revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating income of 624 million yuan, representing a year-on-year decrease of 11.92% [1] - The net profit attributable to shareholders of the listed company was 38.08 million yuan, down 2.54% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 23.81 million yuan, reflecting a year-on-year decline of 5.45% [1]

Group 1 - The core viewpoint of the article highlights that 佛慈制药 (Foci Pharmaceutical) held its 10th meeting of the 8th Board of Directors on October 28, 2025, to review the Q3 2025 report and other documents [1] - For the first half of 2025, 佛慈制药's revenue composition was 99.89% from the pharmaceutical industry and 0.11% from the food industry [1] - As of the report, 佛慈制药's market capitalization stands at 4.6 billion yuan [1] Group 2 - The article also mentions that the A-share market has surpassed 4000 points, indicating a significant market resurgence after a decade of stagnation, with technology leading the market's transformation [1]

Core Insights - The company reported a revenue of 195 million yuan for Q3 2025, representing a year-on-year decline of 7.14% [1] - The net profit attributable to shareholders was 7.9778 million yuan, showing a significant increase of 167.92% year-on-year [1] - Basic earnings per share (EPS) for Q3 2025 stood at 0.0156 yuan [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 624 million yuan, which is a year-on-year decrease of 11.92% [1] - The net profit attributable to shareholders for the first three quarters was 38.0824 million yuan, reflecting a slight decline of 2.54% year-on-year [1] - Basic earnings per share (EPS) for the first three quarters was reported at 0.0746 yuan [1]

Group 1 - The core viewpoint of the article highlights the financial performance of 佛慈制药 for the third quarter of 2025, indicating a decline in revenue and net profit compared to the previous year [1] - The company's revenue for the first three quarters of 2025 is approximately 624 million yuan, representing a year-on-year decrease of 11.92% [1] - The net profit attributable to shareholders of the listed company is about 38.08 million yuan, showing a year-on-year decline of 2.54% [1] - The basic earnings per share is reported at 0.0746 yuan, which is a decrease of 2.48% year-on-year [1] Group 2 - As of the report, 佛慈制药 has a market capitalization of 4.6 billion yuan [2]

一、董事会会议召开情况 证券代码：002644 证券简称：佛慈制药 公告编号：2025-025 兰州佛慈制药股份有限公司 第八届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 兰州佛慈制药股份有限公司（以下简称"公司"）第八届董事会第十次会议于 2025 年 10 月 28 日 9:00 在公司五楼会议室以现场和通讯表决相结合的方式召开， 会议由董事长单小东先生主持。会议通知于 2025 年 10 月 24 日以书面、电子邮 件、电话等方式送达。会议应出席董事 6 人，实际出席董事 6 人。公司高级管理 人员列席会议。本次会议的召开符合《公司法》《公司章程》《董事会议事规则》 及有关法律、法规的规定。 二、董事会会议审议情况 本次会议审议通过以下议案： 本议案已经董事会审计委员会审议通过。 表决结果：6 票同意，0 票反对，0 票弃权。 三、备查文件 1.公司第八届董事会第十次会议决议。 特此公告。 兰州佛慈制药股份有限公司董事会 2025 年 10 月 28 日 1.审议通过了《2025 年第三季度报告》 《2025 年第三季度报告 ...

Revenue and Profit - The company's revenue for Q3 2025 was CNY 194,689,733.90, representing a decrease of 7.14% compared to the same period last year[5] - Total operating revenue for Q3 2025 was CNY 624,055,200.70, a decrease of 11.93% compared to CNY 708,531,496.45 in the same period last year[19] - Net profit attributable to shareholders increased by 167.92% to CNY 7,977,760.05, while the year-to-date net profit decreased by 2.54% to CNY 38,082,371.36[5] - Net profit for Q3 2025 was CNY 37,144,761.73, a decline of 8.99% compared to CNY 40,448,681.79 in Q3 2024[20] - The basic earnings per share for the current period was CNY 0.0156, up 168.97% year-on-year[5] - The company reported a basic and diluted earnings per share (EPS) of 0.0746 CNY, slightly down from 0.0765 CNY in the previous period[21] Cash Flow and Financial Activities - Cash flow from operating activities showed a significant increase of 677.92%, reaching CNY 93,505,221.89[12] - The net cash flow from operating activities was 93,505,221.89 CNY, a significant improvement compared to the previous period's negative cash flow of -16,179,550.59 CNY[21] - Total cash inflow from operating activities reached 615,352,024.64 CNY, up from 556,915,313.50 CNY in the prior period, indicating a growth of approximately 10.5%[21] - The net cash flow from investing activities was -17,798,690.52 CNY, worsening from -8,778,238.96 CNY in the prior period[22] - Cash flow from financing activities showed a net outflow of -23,933,988.62 CNY, an improvement from -29,460,365.54 CNY in the previous period[22] - The company received 14,000,000.00 CNY from borrowings, an increase from 10,000,000.00 CNY in the prior period[22] - The company paid 30,124,520.00 CNY in debt repayments, up from 23,400,000.00 CNY in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,523,957,908.79, an increase of 2.19% from the end of the previous year[5] - The company's total assets increased to CNY 2,523,957,908.79 in Q3 2025 from CNY 2,469,785,308.07 in Q3 2024, reflecting a growth of 2.20%[18] - Total liabilities rose to CNY 678,012,772.88 in Q3 2025, compared to CNY 654,805,874.66 in Q3 2024, marking an increase of 3.54%[18] - Deferred income tax assets increased to CNY 65,761,494.90 from CNY 61,809,926.77, showing a growth of 6.36%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,288[13] - The largest shareholder, Lanzhou Foci Pharmaceutical Industry Development Group Co., Ltd., holds 61.63% of the shares, totaling 314,713,676 shares[13] - There are no significant changes in the top 10 shareholders' participation in margin trading[13] - The company remains unaware of any relationships among other shareholders beyond the known connections[13] Operating Costs and Expenses - Total operating costs for Q3 2025 were CNY 564,312,051.85, down 13.39% from CNY 651,587,799.98 year-over-year[19] - Research and development expenses for Q3 2025 were CNY 18,073,933.17, down 17.00% from CNY 21,768,633.09 in the previous year[19] - The company reported a decrease in sales expenses to CNY 72,223,250.25, down 22.36% from CNY 93,057,848.76 year-over-year[19] Other Financial Metrics - The company recorded a significant increase in other income, with operating income rising by 1202.37% to CNY 429,246.10 due to received compensation for penalties[11] - Financial expenses decreased by 40.20% to CNY -2,607,224.19, attributed to increased interest expenses from loans and reduced interest income from bank deposits[11] - The company has not reported any other non-recurring profit and loss items beyond those specified[6] - The company has no preferred shareholders as indicated in the report[15] - The company's long-term equity investments decreased to ¥50,048,818.67 from ¥55,663,345.27, a decline of about 10.9%[16] - Fixed assets decreased to ¥987,758,000.40 from ¥1,028,543,483.45, reflecting a reduction of approximately 4.0%[16] - The total current assets amounted to ¥1,322,828,440.81, up from ¥1,221,884,081.46, indicating a growth of approximately 8.3%[16] Audit Information - The company did not undergo an audit for the third quarter financial report[23]

一家在中药罐子里浸润了近百年的老字号药企，突然将目光投向了当今医药领域最前沿、最火爆的"核药"赛道。 日前，佛慈制药（002644）发布公告称，为提前布局放射性同位素药物赛道，进一步提升核心竞争力，与科近泰基新技术有限公司（以下简称"科近泰 基"）签订了《增资协议》，以2000万元现金增资科近泰基，增资完成后将持有该公司4.911%股权。 来源：佛慈制药公告 科近泰基公司是中国科学院近代物理研究所医用同位素项目产业化的主体企业，主要业务为协同中国科学院近代物理研究所、甘肃省同位素实验室等开展 医用同位素的生产、销售、运营及药物协作研发。 此番参与增资的还有中国科学院近代物理研究所、甘肃省同位素实验室、甘肃国资、中科创星等多家机构和个人投资者，总融资额达到3.73亿元人民币。 平淡的老字号 佛慈制药是一家具有近百年制药历史的中华老字号。 根据公开资料，其1929 年创建于上海，建厂之初就首创了中药浓缩丸剂型，开启了中药工业化生产的先河。1956年，公司西迁兰州，2011年在深交所首 发上市。2018年，"出城入园"搬迁至兰州新区，很长一段时间里属于兰州市属国企。 正如多数老字号企业，佛慈在基础产品力上功底扎实， ...

Core Insights - 佛慈制药 has made a strategic investment of 20 million yuan in 科近泰基, acquiring a 4.911% stake, marking its entry into the promising field of radioactive isotope therapy [1] - 科近泰基 is a subsidiary of the Chinese Academy of Sciences, focusing on the research and development of ion accelerator technology and medical isotopes for cancer treatment [1][2] - The investment aligns with national innovation strategies and aims to enhance 佛慈制药's competitiveness in the pharmaceutical industry by integrating resources from academia and industry [2][3] Financial and Operational Highlights - The total capital increase for 科近泰基 is approximately 373 million yuan, with 佛慈制药's investment priced at about 1.07 yuan per registered capital [2] - 科近泰基 is currently in the technology investment and business expansion phase, with no profits expected until mid-2025, but it shows steady asset growth and significant technical barriers [2] - The investment is fully funded by 佛慈制药's own capital, ensuring no adverse impact on its current financial status or operational results [3] Strategic Implications - The investment is seen as a response to the urgent market demand for medical isotopes, particularly α-emitting isotopes, which are crucial for precise cancer treatment [2] - By partnering with a national research institution, 佛慈制药 demonstrates its commitment to transitioning into high-tech, high-value sectors within the biopharmaceutical industry [3] - The collaboration is expected to open new growth opportunities for 佛慈制药 and contribute to the development of independent nuclear medicine technologies in China [3]

Core Viewpoint - Lanzhou Foci Pharmaceutical Co., Ltd. has signed an investment agreement with KJT Technology Co., Ltd., marking its entry into the promising field of radioactive isotope drugs [2][3] Group 1: Investment Details - The company invested 20 million yuan in KJT Technology, acquiring a 4.91% stake [2] - KJT Technology is a wholly-owned subsidiary of the Institute of Modern Physics, Chinese Academy of Sciences, focusing on ion accelerator solutions and advanced research equipment [2] Group 2: Strategic Implications - This investment positions the company strategically in the upstream of the nuclear medicine industry, securing core resources for future development in radioactive drug research and production [3] - The collaboration with KJT Technology aligns with national and provincial policies promoting high-end pharmaceutical industries, enhancing the company's competitiveness and technological capabilities [3]

Core Viewpoint - The company, Foci Pharmaceutical (002644.SZ), is strategically investing in the radioactive isotope drug sector to enhance its core competitiveness by signing a capital increase agreement with Kejin Taiji Technology Co., Ltd. for 20 million yuan, acquiring a 4.911% stake in the company by October 10, 2025 [1] Group 1: Investment Details - The investment amount is 20 million yuan, which will result in a 4.911% equity stake in Kejin Taiji Technology Co., Ltd. after the capital increase [1] - The agreement is aimed at positioning the company in the radioactive isotope drug market, which is expected to grow significantly [1] Group 2: Company Background - Kejin Taiji Technology Co., Ltd. is a wholly-owned subsidiary of the Institute of Modern Physics, Chinese Academy of Sciences, primarily engaged in the design and technical services of ion accelerator systems [1] - The company is involved in the construction of a medical isotope drug research and development platform in Lanzhou New Area, focusing on alpha-emitting isotopes like 225Ac and 223Ra for cancer treatment [1] Group 3: Future Business Focus - Post-investment, Kejin Taiji Technology Co., Ltd. will collaborate with the Institute of Modern Physics and Gansu Isotope Laboratory to produce, sell, and develop medical isotopes and related drugs [1] - The goal is to achieve breakthroughs in the mass production of alpha-emitting isotopes and ensure the autonomy of key technologies and equipment [1]